Mid-Atlantic BioTherapeutics (MABT)

Mid-Atlantic BioTherapeutics (MABT) is a clinical-stage pharmaceutical company based in the United States, founded in 2011 with a focus on eradicating infectious diseases. The company utilizes a pioneering technology platform called IMT504, which harnesses the body’s immune response to combat challenging infections. With impressive results in animal safety and efficacy models, as well as in humans, IMT504 stands out as a proprietary, revolutionary molecule with a strong safety and immunostimulatory profile. As a leader in immunotherapy for infectious diseases, MABT plays a vital role in addressing antibiotic resistance, providing an alternative to existing treatments for viral conditions such as influenza, and contributing to biodefense efforts. Notably, the company has received Orphan Drug Designation for late-stage rabies disease, offering a unique pathway to FDA approval and extended market exclusivity. MABT's groundbreaking technology has attracted significant funding, with the founders having invested over $23M to date. The most recent investment of $5.00M came from SMITM Capital Markets in a Venture Round in June 19, 2024. Through their continued investment, MABT aims to advance its innovative therapies and make a meaningful impact on disease treatment.